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blood	 plasma	was	 collected	 to	measure	 the	 serotonin	 precursor	 tryptophan	 (TRP),	
KYN,	 the	KYN/TRP	ratio,	and	neopterin	 levels.	Statistical	analyses	were	conducted	












into	 the	 effect	 of	 inflammation	 on	 sleep	 in	 BD	 may	 lead	 to	 clinical	 markers	 of	
outcome.










shows	 that	 BD	 presents	with	 numerous	 immune-	inflammatory	 and	
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sleep	 abnormalities.6-8	Activation	 of	 the	 kynurenine	 (KYN)	 pathway	
has	 been	 supported	 in	 a	 number	 of	 psychiatric	 disorders,	 including	
BD9,10.While	 many	 studies	 have	 independently	 explored	 sleep,11-13 
inflammation,7,14	and	the	KYN9,15	pathway	in	BD,	there	is	increasing	






















[5-	HT])	 pathway	 and	 the	 KYN	 pathway	 (Figure	1).	 During	 stress,	
proinflammatory	 cytokines	 activate	 the	 KYN	 pathway	 and	 deprive	
the	 serotonin	 pathway	 of	 TRP,	 thereby	 reducing	 serotonin	 syn-
thesis.	The	 dynamics	 of	 this	 process	 are	 characterized	 best	 by	 the	
kynurenine-	to-	TRP	(KYN/TRP)	ratio.	One	of	the	inflammatory	drivers	
of	this	diversion	of	serotonin	to	KYN	is	neopterin,	a	catabolic	prod-
uct	 of	 guanosine	 triphosphate	 that	 is	 a	 marker	 of	 cellular	 immune	
system	 activation	 produced	 by	 macrophages	 upon	 stimulation	 by	
interferon-	gamma.25-28	Increased	peripheral	KYN	results	in	increased	
central	KYN.	KYN	is	further	broken	down	into	quinolinic	acid,	which	
is	 a	 potent	 agonist	 at	 the	N-	methyl-	D-	aspartate	 (NMDA)	 receptor,	
causing	excitotoxic	effects	 through	 receptor	overactivation29,30 and 
inhibiting	glutamate	uptake,	causing	elevated	extracellular	glutamate	
concentrations.31
In	 the	 current	 study,	 we	 investigated	 the	 relationship	 between	
markers	of	the	KYN	pathway,	neopterin,	sleep,	and	clinical	symptoms	




1. Patients	with	 acute	BD	would	have	 significantly	 lower	 total	TRP	
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at	 the	Pennsylvania	Psychiatric	 Institute,	under	 Institutional	Review	















Structured	 clinical	 interview	 based	 on	 the	 Mini	 Neuropsychiatric	
Interview32	 were	 conducted	 and	 current	 mood	 state	 was	 assessed	
using	 the	 Hamilton	 Depression	 Rating	 Scale-	21	 plus	 atypical	 items	
(HDRS-	21+AT),33	 and	 the	 Clinician-	Administered	 Rating	 Scale	 for	
Mania	 (CARS-	M).34	A	combination	of	clinically	significant	manic	and	









from	 the	hospital	or	partial	 hospital	program,	participants	were	 fol-
lowed	 each	 week	 by	 telephone	 and	 assessed	 for	 clinical	 improve-
ment.	A	return	visit	was	scheduled	to	collect	a	second	blood	sample	
when	the	subject	was	asymptomatic,	or	after	3	months	had	elapsed.	
Additional	 measures	 were	 collected	 but	 not	 used	 for	 this	 analysis.	
Saunders	et	al35	provided	a	more	detailed	report	on	the	methods	and	
results	of	analysis	of	fatty	acid	concentrations.
2.3 | Objective measure of total sleep time
During	the	period	of	initial	evaluation,	participants	wore	an	actigraph	
(Sleepwatch-	O,	 Ambulatory	 Monitoring,	 Inc.,	 Ardsley,	 NY,	 USA),	 a	





sleep	 variables,	 including	 total	 sleep	 time,	 bedtime	 variability,	 sleep	





analysis	of	mean	 lag	 (variability	 in	bedtime	from	night	 to	night)	was	
also	made.
2.4 | Sample collection and biochemical analysis
Participants	 fasted	for	at	 least	6	hours,	and	blood	was	drawn	 in	va-
cutainers	 containing	 ethylenediaminetetraacetic	 acid	 (EDTA)	 in	
the	morning.	 BD	participants	 had	 blood	 drawn	between	07:15	 and	








per	millimoles	 of	 TRP).	 Neopterin	was	measured	 by	 enzyme-	linked	
immunosorbent	 assay	 (BRAHMS,	 Hennigsdorf,	 Germany)	 according	
to	the	manufacturer’s	instructions,	with	a	detection	limit	of	2	nmol/L.
2.5 | Data and statistical analysis





and	 follow-	up	 measurements.	 In	 an	 exploratory	 analysis,	 Pearson’s	
r	was	used	 for	separate	bivariate	correlations	on	demographics	and	
clinical	 symptoms,	 sleep,	 and	 inflammation	 variables	 in	 the	BD	 and	
HC	samples.	Baseline	depression	was	predicted	using	 linear	 regres-




































evaluated	 for	 the	 study	 exhibited,	 on	 average,	 severe	 depressive	
symptoms	and	moderate	manic	symptoms	(Table	1).
3.2 | Sleep and inflammation variables
The	HC	 group	 slept	 an	 average	 of	 6.9	hours	 a	 night,	with	 a	 stand-







3.2.1 | Group comparisons of TRP, KYN/TRP, and  
neopterin
As	hypothesized,	the	BD	group	had	significantly	lower	levels	of	TRP	
than	 the	HC	 group	 (P	<	.03)	 (Table	1).	 The	BD	 group	 did	 not	 differ	
significantly	from	the	HC	group	in	mean	levels	of	KYN,	KYN/TRP,	and	
neopterin	(Table	1).
3.2.2 | TRP, KYN/TRP, and neopterin, and severity of 
depressive and manic symptoms
Based	on	Pearson’s	 correlation	 test,	KYN,	KYN/TRP,	 and	neopterin	
did	not	correlate	significantly	with	depressive	and	manic	symptoms,	
as	measured	 by	 the	HDRS	 and	 CARS-	M	 clinical	measures	 or	 sleep	





3.2.3 | Association of biomarkers and sleep with 
depressive and manic severity
The	 association	of	 depressive	 severity	was	 tested	with	 four	 hierar-
chical	regression	models,	using	depressive	severity	as	the	dependent	
variable	and	total	sleep	time,	KYN,	TRP,	and	KYN/TRP	as	the	predic-




Healthy control Bipolar disorder
PN (%) N (%)
Total	sample	size 28 21
Gender	(F) 16	(57%) 10	(48%) .57
Race











Smoking	status 1	(4%/) 11	(52%) <.001
Mean (SD) Mean (SD)




Mania	(CARS-	M) 0 16.52	(13.87) <.001







KYN	(μmol/L) 1.98	(.55) 1.79	(.50) .22
TRP	(μmol/L) 68.74	(11.62) 60.25	(14.30) .03
KYN/TRP 28.93	(7.26) 29.88	(6.21) .63
Neopterin	(nmol/L) 5.45	(1.39) 5.80	(1.66) .46
KYN,	kynurenine;	Kyn/Trp,	kynurenine/tryptophan	ratio;	SD,	standard	
deviation;	TRP,	tryptophan.





cance,	 accounting	 for	60%	of	 the	variance	 (Table	4).	Although	 total	
sleep	time	was	significantly	associated	with	manic	severity	in	all	four	




















ing	of	 lower	TRP	 levels	 in	acutely	symptomatic	BD	participants	was	
concordant	with	 several	 recent	 reports	 examining	TRP	 levels	 in	 BD	
and	schizophrenia10,39,40	 and	 the	 theory	 that	decreased	plasma	TRP	
levels	 in	BD	participants	may	potentially	 lead	 to	dysfunctional	brain	















HDRS21 CARS-	M BMI Total	sleep	time Mean	lag TRP KYN Kyn/Trp Neopterin
HDRS21 −0.62** 0.11 0.72** −0.32 0.36 0.44 0.14 −0.11
CARS-	M −0.05 −0.52* 0.32 −0.04 −0.25 −0.25 0.36
BMI −0.03 0.21 −0.46* −0.04 0.38 0.24
Total	sleep	time −0.25 0.21 0.03 −0.26 −0.34
Mean	lag −0.05 0.21 0.33 0.25








BMI Total sleep time Mean lag TRP KYN Kyn/Trp Neopterin
BMI −0.25 0.04 −0.12 −0.08 0.01 −0.010
Total	sleep	time −0.12 −0.07 −0.19 −0.14 0.01
Mean	lag −0.23 0.12 0.31 0.32















warranted.	 For	 example,	 one	 study25	 found	 that	 significantly	 higher	


















the	kynurenine	pathway	potentially	 suggests	 the	association	of	 sleep	
and	the	kynurenine	metabolites	with	mood	states.	While	we	did	not	find	
a	 correlation	between	 these	biomarkers	 and	 severity	of	mood	 symp-
toms,	we	found	an	association	with	the	severity	of	clinical	mood	symp-









Finally,	 we	 asked	whether	 total	 sleep	 time,	 TRP,	 and	 KYN/TRP	
changed	 with	 symptom	 remission	 in	 asymptomatic	 BD	 patients.	
Despite	 subjectively	 reported	 decreased	 clinical	 symptoms,	 no	 dif-
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sleep	time.	However,	sleep	is	a	complex	phenomenon	and	consists	of	
multiple	aspects	which	are	easily	measured	using	actigraphic	devices.	













of	mood	 severity	 in	 acutely	 symptomatic	 BD	participants	with	me-
tabolites	of	the	KYN	pathway,	in	association	with	objective	measure-
ments	of	sleep.	Further	understanding	of	the	role	of	in	BD	is	important	
for	 the	 development	 of	 potential	 targets	 for	 intervention,	 or	mark-
ers	of	treatment	response.	Targeting	sleep	and	regulation	of	the	TRP	
breakdown	pathway	for	intervention	in	BD	participants	is	an	area	of	
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